Global Companion Animal Pharmaceuticals Market Overview: Trends Shaping Growth to 2029
Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Market Value Is The Companion Animal Pharmaceuticals Industry Expected To Reach By 2029, Starting From 2025 Levels?
The companion animal pharmaceuticals market has shown robust expansion in recent years. It is anticipated to increase from $16.49 billion in 2024 to $17.85 billion in 2025, achieving a compound annual growth rate (CAGR) of 8.2%. This historical growth can be ascribed to several factors, including the humanization of pets, widespread preventive healthcare measures, a surge in pet insurance adoption, shifts in lifestyle and urbanization, concerns related to zoonotic diseases, and enhanced accessibility to veterinary healthcare.
The companion animal pharmaceuticals market is anticipated to experience substantial expansion over the coming years. This sector is projected to reach a valuation of $26.34 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 10.2%. Key factors contributing to this projected increase include the development of personalized medicine for pets, the rise of telehealth and remote veterinary services, a greater emphasis on nutrition and nutraceuticals, the adoption of one health initiatives, and the broadening scope of veterinary diagnostic services. Furthermore, significant developments expected during this period involve breakthroughs in veterinary medicine, the introduction of specialized treatments for older companion animals, adherence to regulatory compliance and safety standards, and strategic collaborations and partnerships.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7983&type=smp
Which Factors And Drivers Are Influencing The Companion Animal Pharmaceuticals Market In 2025?
The increasing prevalence of zoonotic diseases is anticipated to propel the growth of the companion animal pharmaceuticals market. Zoonotic illnesses are diseases capable of naturally transferring between vertebrate animals and humans. To combat these conditions and mitigate transmission risks, the pharmaceutical industry is implementing modern strategies consistent with a unified set of health principles. For instance, in December 2022, a report from the European Centre for Disease Prevention and Control, a Sweden-based government agency, highlighted that Campylobacteriosis remained the most prevalent zoonosis, with reported cases notably increasing to 127,840 in 2022. The majority of these Campylobacteriosis cases were attributed to chicken and turkey meat. Salmonella, the second most common zoonosis, affected 60,050 individuals. Following Campylobacteriosis and Salmonellosis, the most frequently reported zoonotic diseases included Yersiniosis (6,789 cases), Shigatoxin-producing E. coli infections (6,084 cases), and Listeriosis (2,183 cases). Therefore, the rising prevalence of zoonotic diseases is a key driver for the growth of the companion animal pharmaceuticals market.
What Are The Leading Segments Analyzed In The Companion Animal Pharmaceuticals Market?
The companion animal pharmaceuticals market covered in this report is segmented –
1) By Animal Type: Dogs, Cats, Horses, Other Companion Animals
2) By Indication: Infectious Diseases, Dermatologic Diseases, Pain, Orthopedic Diseases, Behavioral Diseases, Other Indications
3) By Distribution Channels: Veterinary Hospitals, Veterinary Clinics, Retail Pharmacies
Subsegments:
1)By Dogs: Vaccines, Antiparasitic, Anti-Inflammatory Drugs
2) By Cats: Vaccines, Antiparasitic, Anti-Inflammatory Drugs
3) By Horses: Vaccines, Antiparasitic, Anti-Inflammatory Drugs
4) By Other Companion Animals: Vaccines, Antiparasitic, Other Therapeutics
What Long-Term Trends Will Shape The Future Growth Of The Companion Animal Pharmaceuticals Industry?
The integration of big data technologies is emerging as a significant and growing trend in companion animal pharmaceuticals. Major companies operating within the companion animal pharmaceuticals market are strategically concentrating on developing advanced technological solutions to strengthen their competitive standing. For instance, in April 2022, Elanco Animal Health Incorporated, a US-based company active in companion animal pharmaceuticals, partnered with Ginkgo Bioworks, another US-based company operating in companion animal pharmaceuticals, to establish BiomEdit, a microbiome innovation company focused on driving innovation in animal health. This initiative is designed to offer novel probiotics and other related animal pharmaceuticals for advancements in animal health, encompassing aspects like medicated feed ingredients, nutritional health and therapies for livestock and pet animals, and biosecurity technologies for monitoring animal illnesses.
Which Major Firms Are Strengthening Their Position In The Companion Animal Pharmaceuticals Industry?
Major companies operating in the companion animal pharmaceuticals market are Elanco Animal Health Incorporated, Boehringer Ingelheim International GmbH, Ceva Santé Animale, Chanelle Pharma, Eco Animal Health Group PLC, Ashish Life Science Pvt. Ltd., Endovac Animal Health, Hipra Laboratories, Indian Immunologicals Ltd., Inovet Group, Kyoritsu Seiyaku Corporation, Lutim Pharma Pvt. Ltd., Merck & Co. Inc., Norbrook Laboratories Ltd., Tianjin Ringpu Bio-Technology Co. Ltd., Vetoquinol S.A., Virbac S.A., Zoetis Inc., Agrolabo S.p.A., ALS Pvt. Ltd., Zydus Animal Health and Investments Limited, Eli Lilly and Company, IDEXX Laboratories Inc., Merial Limited, Novartis Animal Health Inc., Dechra Pharmaceuticals PLC, Aratana Therapeutics Inc., Phibro Animal Health Corporation, Kindred Biosciences Inc., Jaguar Health Inc., Nexvet Biopharma PLC, Sentinel Biomedical Inc., PetMed Express Inc., Neogen Corporation, Heska Corporation, Synbiotics Corporation, Eurovet Animal Health B.V., Vironova AB, Abaxis Inc., Bioiberica S.A.U., Putney Inc., Lohmann Animal Health International
Download The Full Report For Exclusive Market Findings:
Which Region Shows The Highest Potential For Future Expansion In The Companion Animal Pharmaceuticals Market?
North America was the largest region in the companion animal pharmaceuticals market in 2024. Asia-Pacific is expected to be the fastest-growing region in the companion animal pharmaceuticals market report during the forecast period. The regions covered in the companion animal pharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Companion Animal Pharmaceuticals Market Report:
https://www.thebusinessresearchcompany.com/customise?id=7983&type=smp
Browse Through More Reports Similar to the Global Companion Animal Pharmaceuticals Market 2025, By The Business Research Company
Companion Animal Veterinary Vaccines Global Market Report 2025
Animal Medicine Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/animal-medicine-global-market-report
Animal Antibiotics And Antimicrobials Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
